Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I repeated-application study of SKE-18 1% cream in rosacea-associated persistent facial erythema
jRCT2031240257Phase 1Completed
- Sponsor
- Sato Pharmaceutical
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of epinastine hydrochloride in rosacea (2 arms), sponsored by Sato Pharmaceutical. Primary endpoints: Pharmacokinetic parameters of SKE-18 and Plasma concentration-time profile of SKE-18. Started Sep 2024; status: completed.
02
Drugs
epinastine hydrochloride
03
Conditions
rosacea
Beyond the preview
Go deeper on jRCT2031240257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240257.